Log in

Aemetis Stock Price, News & Analysis (NASDAQ:AMTX)

+0.01 (+1.00 %)
(As of 10/23/2019 03:20 AM ET)
Today's Range
Now: $1.01
50-Day Range
MA: $1.03
52-Week Range
Now: $1.01
Volume18,222 shs
Average Volume221,595 shs
Market Capitalization$20.78 million
P/E RatioN/A
Dividend YieldN/A
Aemetis, Inc operates as a renewable fuels and bio-chemicals company in North America and India. The company focuses on the acquisition, development, and commercialization of various technologies that replace traditional petroleum-based products through the conversion of ethanol and biodiesel plants into advanced bio refineries. It owns and operates an ethanol plant in the California Central Valley near Modesto; and a biodiesel plant in Kakinada, India. Read More…

Industry, Sector and Symbol

Industry Industrial organic chemicals
Current SymbolNASDAQ:AMTX



Sales & Book Value

Annual Sales$171.53 million
Book Value($5.68) per share


Net Income$-33,020,000.00


Market Cap$20.78 million
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable

Receive AMTX News and Ratings via Email

Sign-up to receive the latest news and ratings for AMTX and its competitors with MarketBeat's FREE daily newsletter.

Aemetis (NASDAQ:AMTX) Frequently Asked Questions

What is Aemetis' stock symbol?

Aemetis trades on the NASDAQ under the ticker symbol "AMTX."

How were Aemetis' earnings last quarter?

Aemetis Inc (NASDAQ:AMTX) released its quarterly earnings data on Thursday, August, 8th. The specialty chemicals company reported ($0.33) EPS for the quarter. The specialty chemicals company had revenue of $50.62 million for the quarter. View Aemetis' Earnings History.

When is Aemetis' next earnings date?

Aemetis is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Aemetis.

What is the consensus analysts' recommendation for Aemetis?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aemetis in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aemetis.

Has Aemetis been receiving favorable news coverage?

Press coverage about AMTX stock has trended negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Aemetis earned a news impact score of -2.3 on InfoTrie's scale. They also assigned news articles about the specialty chemicals company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Aemetis.

Are investors shorting Aemetis?

Aemetis saw a drop in short interest in the month of September. As of September 30th, there was short interest totalling 107,100 shares, a drop of 12.1% from the August 30th total of 121,900 shares. Based on an average daily trading volume, of 79,100 shares, the short-interest ratio is presently 1.4 days. Currently, 0.7% of the company's stock are sold short. View Aemetis' Current Options Chain.

Who are some of Aemetis' key competitors?

What other stocks do shareholders of Aemetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aemetis investors own include InterDigital Wireless (IDCC), Stag Industrial (STAG), Wirecard (WDI), Magnegas Applied Tchnlgy Sltns (MNGA), NuCana (NCNA), Pacific Ethanol (PEIX), Procter & Gamble (PG), Achaogen (AKAO), Gevo (GEVO) and Intuitive Surgical (ISRG).

Who are Aemetis' key executives?

Aemetis' management team includes the folowing people:
  • Mr. Eric A. McAfee, Co-Founder, Exec. Chairman, CEO & Pres (Age 56)
  • Mr. Todd A. Waltz, Exec. VP, CFO & Sec. (Age 58)
  • Mr. Andrew B. Foster, Exec. VP & COO (Age 54)
  • Mr. Sanjeev Gupta, Exec. VP & MD, Chairman and Pres of Universal Biofuels Pvt. Ltd. (Age 59)

Who are Aemetis' major shareholders?

Aemetis' stock is owned by many different of retail and institutional investors. Top institutional investors include CIBC Private Wealth Group LLC (5.12%). View Institutional Ownership Trends for Aemetis.

Which major investors are selling Aemetis stock?

AMTX stock was sold by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC. View Insider Buying and Selling for Aemetis.

How do I buy shares of Aemetis?

Shares of AMTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aemetis' stock price today?

One share of AMTX stock can currently be purchased for approximately $1.01.

How big of a company is Aemetis?

Aemetis has a market capitalization of $20.78 million and generates $171.53 million in revenue each year. Aemetis employs 152 workers across the globe.View Additional Information About Aemetis.

What is Aemetis' official website?

The official website for Aemetis is http://www.aemetis.com/.

How can I contact Aemetis?

Aemetis' mailing address is 20400 STEVENS CREEK BLVD SUITE 700, CUPERTINO CA, 95014. The specialty chemicals company can be reached via phone at 408-517-3304 or via email at [email protected]

MarketBeat Community Rating for Aemetis (NASDAQ AMTX)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  121 (Vote Outperform)
Underperform Votes:  152 (Vote Underperform)
Total Votes:  273
MarketBeat's community ratings are surveys of what our community members think about Aemetis and other stocks. Vote "Outperform" if you believe AMTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel